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Sir,
Antimicrobial susceptibility testing (AST) reports are used by clin-
icians to guide antibiotic treatment of patients suffering from
infectious diseases. AST reports, such as those based on the Kirby–
Bauer disc diffusion test, in general do not include raw data, but an
interpretation of the data in clinical categories (resistant, inter-
mediate, susceptible), which reflect the likelihood of therapeutic
success.1 This practice is intended to provide clinicians with clear
and unambiguous clinical information. However, it entails a major
loss of data. In contrast to results from clinical chemistry or
haematology, where methodological precision measurements
and quantitative results are implemented in the reports, these are
absent in AST reports, where a mere classification into clinical cate-
gories is performed on the basis of inhibition zone measurements
or MIC determinations. As a consequence, AST reports do not allow
estimation of the probabilities of miscategorization, especially for
measurements close to the clinical breakpoints (CBPs), where the
error probability is higher.2,3
Since 2014, AST categorization of most drug/species combin-
ations has depended exclusively on MIC and/or inhibition zone
measurements.4 However, AST methods still suffer from a not-
able methodological variability, which can lead to miscategoriza-
tion of a clinical isolate. Different miscategorization types are
defined on the basis of the therapeutic implications. Erratic clas-
sifications of true-susceptible isolates as resistant are considered
major errors (MEs), misclassifications of true-resistant isolates as
susceptible are referred to as very major errors (vMEs) and false
assignments of bacterial isolates to adjacent interpretative
categories (S!I, I!S, I!R) are considered minor errors (mEs).
The rates of MEs, vMEs and mEs depend on a number of factors:
(i) presence and width of an intermediate zone; (ii) position of a
population relative to the CBP; and (iii) methodological variation.
The latter parameter includes both the methodological impreci-
sion (inoculum size, agar composition, incubation time, disc con-
tent, inter- and intra-person variability in the reading) and the
biological variation.5
Here we report on Antibiotrust, a software that visualizes the
antibiogram and the reliability of the categorization. Antibiotrust
was developed with the aim of conveying a graphic report display-
ing AST data from Kirby–Bauer disc diffusion testing. However, this
approach can also be used for data based on MIC determination.
As shown in Figure 1, Antibiotrust reports display the inhibition
zone diameters of antibiotic panels used for the various bacterial
groups (e.g. Enterobacteriaceae). The rectangular boxes corres-
pond to the various antibiotics and are partitioned into the inter-
pretative categories [resistant (r) in red, intermediate (i) in yellow
and susceptible (s) in green]. Inhibition zone diameter distributions
within the susceptible WT population appear in green shades,
which become darker with higher prevalences. The distributions
are based on local data and are updated each year. This feature is
particularly relevant for susceptible clinical isolates, as it visualizes
the position of the tested clinical isolate relative to the distribution
of the WT population as derived from local epidemiological data.
Black boxes and error bars indicate the inhibition zone diameter
along with the methodological variation. The latter significantly in-
fluences the classification reliability and thereby the rate of MEs
and vMEs.3 The width of the error bars is continuously updated for
each combination of antibiotic and species or bacterial group and
is given by the 2-fold standard deviation of weekly repeated meas-
urements of inhibition zones of a quality-control strain. The inter-
pretative category is displayed on the left side of the antibiotic box
and is accompanied by the reliability of the categorization, which is
calculated separately for all antibiotics using a normal model.2
Intrinsic antibiotic resistances are displayed in blue (e.g. ampicillin
for Klebsiella pneumoniae). Monochromatic boxes display inter-
pretative categorizations that are deduced from other antibiotics
(i.e. ciprofloxacin and levofloxacin from norfloxacin) in agreement
with EUCAST-derived in-house expert interpretation rules.6
Reliabilities are not determined for intrinsic resistances, deduced
interpretations and for antibiotic/species combinations classified
as intermediate.
Several studies have shown a good correlation between MIC
values and inhibition zone diameters in several bacterial species.7,8
A prospective integration of MIC values inferred from disc diffusion
assays by Antibiotrust may further advance the accuracy of the
AST reports and allow a better estimate of the antimicrobial sus-
ceptibility patterns.
The additional information provided by Antibiotrust will help in
choosing the most appropriate antibiotic, as clinicians will be in the
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position to select the drug with the highest reliability of categoriza-
tion and thus likelihood of therapeutic success.
In conclusion, we describe an automated visualization software
that includes indicators of interpretation reliability in AST reports
based on the local epidemiological situation and methodological
variation. The integration of reliabilities of misclassifications to-
gether with a graphic visualization will allow improved therapeutic
decision making based on AST reports.
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Figure 1. Antibiogram visualized with Antibiotrust. The graphic report of a Kirby–Bauer antibiotic testing of a K. pneumoniae strain isolated from an in-
patient at the University Hospital of Zu¨rich is depicted.
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Sir,
Recently, Bryce et al.1 showed in a prospective study that the preva-
lence of resistance to antibiotics in urinary Escherichia coli isolates
obtained from children ,5 years of age was high. For example, the
prevalences of resistance to amoxicillin and trimethoprim, two anti-
biotics recommended for the treatment of lower urinary tract
infection (UTI) in children,2 were approximately 50% and 28%, re-
spectively (Table 1).1,3 In contrast, all isolates were susceptible to
nitrofurantoin.1,2 To improve the certainty on the actual prevalence
of resistance in England, a larger sample size is needed. In response
to the relatively high prevalence of trimethoprim resistance in iso-
lates from adults, guidelines have been revised recently and now
recommend nitrofurantoin be used over trimethoprim as a first-line
treatment for uncomplicated UTIs in adults.2,4 However, Bryce
et al.1 speculated that the same recommendation has not been
made for children due to the absence of resistance data for this age
group in the UK. NICE are currently reviewing the antibiotic treat-
ment recommendations for children and adults.5
PHE’s national laboratory surveillance system, Second
Generation Surveillance System (SGSS), captures data supplied
electronically by 98% of hospital microbiology laboratories in
England. SGSS records contain results for all antimicrobials tested
(including results suppressed from clinical reports) for isolates
from all clinical specimen types as well as demographic patient in-
formation such as age and gender.6 A limitation of using urine
specimens recorded in SGSS is that samples may be more likely to
be tested if a patient has risk factors for antibiotic resistance, po-
tentially leading to overestimation of resistance prevalence.
However, among infants and children ,3 years of age the preva-
lence should not be systematically overestimated as national
guidance recommends to always send a sample in case of symp-
toms suggestive of UTI.2 For children aged 3 years, the preva-
lence might be overestimated to a certain extent as current NICE
guidance recommends sending a sample for culture only if the pa-
tient is at risk of serious illness and/or has a history of recurrent UTI,
if both leucocyte esterase and nitrite are positive.2
Here we evaluated whether, when using these national data, the
estimated prevalence of resistance to antibiotics in urinary E. coli iso-
lates obtained from children ,5 years of age was concordant with
the results of Bryce et al.1 We restricted our analysis to one financial
year (April 2014 to March 2015) (as compared with 2010 to 2013 in
Bryce et al.1) and only included samples received from general prac-
tices (as compared with primary care and emergency department
presentations in Bryce et al.1). Repeat specimen reports received
from the same patient with matching causative agents were ex-
cluded if the specimen dates were within 90 days. We focused on
antibiotics recommended for treatment of UTI in children and
for which at least 75% of the urinary E. coli samples included sus-
ceptibility test results: trimethoprim (99%), nitrofurantoin (99%), co-
amoxiclav (93%), ciprofloxacin (82%), cefalexin (82%) and amoxicil-
lin (77%). We observed similar prevalences of resistance to Bryce
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